Rhee, Joon Haeng

Republic of Korea

Back to Profile

1-5 of 5 for Rhee, Joon Haeng Sort by
Query
Aggregations
Date
2021 1
Before 2020 4
IPC Class
A61K 39/106 - VibrioCampylobacter 3
A61K 39/00 - Medicinal preparations containing antigens or antibodies 2
A61K 39/02 - Bacterial antigens 2
A61K 39/12 - Viral antigens 2
A61K 9/00 - Medicinal preparations characterised by special physical form 2
See more
Found results for  patents

1.

Preparation of flagellin vaccine adjuvant-based vaccine to induce production of antibody recognizing conformation of antigens, and application thereof

      
Application Number 17116104
Grant Number 11771753
Status In Force
Filing Date 2020-12-09
First Publication Date 2021-04-08
Grant Date 2023-10-03
Owner
  • RHEE, JOON HAENG (Republic of Korea)
  • LEE, SHEE EUN (Republic of Korea)
  • JEONG, KWANG JOON (Republic of Korea)
Inventor
  • Rhee, Joon Haeng
  • Lee, Shee Eun
  • Jeong, Kwangjoon
  • Park, Sang Chul
  • Tan, Wenzhi

Abstract

The present invention provides a vaccine composition for use in neurodegenerative diseases and an infectious virus vaccine composition for inducing an antibody recognizing the conformation of antigens. The vaccine composition of the present invention induces the production of an antibody recognizing the conformation of antigens. The antibody recognizing the conformation of antigens has high specificity for an antigen, and thus can be useful for ameliorating, preventing or treating diseases.

IPC Classes  ?

  • A61K 39/02 - Bacterial antigens
  • C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 35/68 - Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 39/12 - Viral antigens
  • A61P 31/18 - Antivirals for RNA viruses for HIV

2.

Preparation of flagellin vaccine adjuvant-based vaccine to induce production of antibody recognizing conformation of antigens, and application thereof

      
Application Number 16312510
Grant Number 10953082
Status In Force
Filing Date 2016-11-17
First Publication Date 2019-05-30
Grant Date 2021-03-23
Owner
  • RHEE, JOON HAENG (Republic of Korea)
  • LEE, SHEE EUN (Republic of Korea)
  • JEONG, KWANG JOON (Republic of Korea)
Inventor
  • Rhee, Joon Haeng
  • Lee, Shee Eun
  • Jeong, Kwangjoon
  • Park, Sang Chul
  • Tan, Wenzhi

Abstract

The present invention provides a vaccine composition for use in neurodegenerative diseases and an infectious virus vaccine composition for inducing an antibody recognizing the conformation of antigens. The vaccine composition of the present invention induces the production of an antibody recognizing the conformation of antigens. The antibody recognizing the conformation of antigens has high specificity for an antigen, and thus can be useful for ameliorating, preventing or treating diseases.

IPC Classes  ?

  • A61K 39/02 - Bacterial antigens
  • C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/12 - Viral antigens
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 31/18 - Antivirals for RNA viruses for HIV

3.

Modified flagellin improved toll-like receptor 5 stimulating activity

      
Application Number 13333857
Grant Number 08337865
Status In Force
Filing Date 2011-12-21
First Publication Date 2012-08-09
Grant Date 2012-12-25
Owner
  • RHEE, JOON HAENG (Republic of Korea)
  • LEE, SHEE EUN (Republic of Korea)
Inventor
  • Rhee, Joon Haeng
  • Lee, Shee Eun
  • Kim, Soo Young

Abstract

Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin.

IPC Classes  ?

4.

Modified flagellin improved toll-like receptor 5 stimulating activity

      
Application Number 13333709
Grant Number 08337864
Status In Force
Filing Date 2011-12-21
First Publication Date 2012-08-09
Grant Date 2012-12-25
Owner
  • RHEE, JOON HAENG (Republic of Korea)
  • LEE, SHEE EUN (Republic of Korea)
Inventor
  • Rhee, Joon Haeng
  • Lee, Shee Eun
  • Kim, Soo Young

Abstract

Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin.

IPC Classes  ?

5.

Modified flagellin improved toll-like receptor 5 stimulating activity

      
Application Number 12526187
Grant Number 08236327
Status In Force
Filing Date 2008-02-05
First Publication Date 2011-01-13
Grant Date 2012-08-07
Owner
  • RHEE, JOON HAENG (Republic of Korea)
  • LEE, SHEE EUN (Republic of Korea)
Inventor
  • Rhee, Joon Haeng
  • Lee, Shee Eun
  • Kim, Soo Young

Abstract

Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin.

IPC Classes  ?